Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)
- PMID: 9210410
- PMCID: PMC1218502
- DOI: 10.1042/bj3240855
Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)
Abstract
The type-III deletion variant of the epidermal growth factor receptor (EGFRvIII) is frequently found in glioblastomas and other malignant human tumours. Although EGFRvIII confers ligand-independent oncogenic transformation of cell lines, the mechanism by which it promotes aberrant cellular proliferation is unknown. Using cell lines expressing comparable numbers of either wild-type receptor (EGFRwt) or EGFRvIII, we compared several parameters of receptor activation: dimerization, tyrosine phosphorylation and activation of intracellular signalling proteins. Like activated EGFRwt, EGFRvIII was phosphorylated and bound constitutively to the Shc adapter protein. Indeed, EGFRvIII-associated Shc had a higher phosphotyrosine content than Shc associated with stimulated EGFRwt. EGFRwt dimerized in response to either EGF or transforming growth factor alpha. Higher cross-linker concentrations and incubation at higher temperatures (37 degrees C) allowed detection of EGFRwt dimers even in the absence of exogenous ligand. In contrast, EGFRvIII failed to dimerize under any conditions studied. Moreover, neither mitogen-activated protein kinase nor phospholipase Cgamma were phosphorylated in EGFRvIII-expressing cells. We conclude that the deletion of 267 amino acids from the 621-amino-acid N-terminal domain of EGFR does not result simply in a constitutively activated receptor, but alters the spectrum of signalling cascades utilized. Furthermore the ligand-independent transforming activity of EGFRvIII is independent of receptor dimerization.
Similar articles
-
An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.Oncogene. 2014 Aug 14;33(33):4253-64. doi: 10.1038/onc.2013.400. Epub 2013 Sep 30. Oncogene. 2014. PMID: 24077285 Free PMC article.
-
Formation of EGFRwt/EGFRvIII homo- and hetero-dimers in glioblastoma cells as detected by single molecule localization microscopy.Nanoscale. 2024 Aug 15;16(32):15240-15255. doi: 10.1039/d4nr01570c. Nanoscale. 2024. PMID: 39073345
-
EGFRvIII-mediated radioresistance through a strong cytoprotective response.Oncogene. 2003 Aug 28;22(36):5545-53. doi: 10.1038/sj.onc.1206788. Oncogene. 2003. PMID: 12944901
-
Ligand-Independent EGFR Signaling.Cancer Res. 2015 Sep 1;75(17):3436-41. doi: 10.1158/0008-5472.CAN-15-0989. Epub 2015 Aug 17. Cancer Res. 2015. PMID: 26282175 Free PMC article. Review.
-
Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.Brain Pathol. 2011 Sep;21(5):479-500. doi: 10.1111/j.1750-3639.2011.00505.x. Epub 2011 Jul 7. Brain Pathol. 2011. PMID: 21615592 Free PMC article. Review.
Cited by
-
Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma.Onco Targets Ther. 2013 Apr 18;6:427-35. doi: 10.2147/OTT.S30373. Print 2013. Onco Targets Ther. 2013. PMID: 23723710 Free PMC article.
-
Immunotherapy of malignant brain tumors.Immunol Rev. 2008 Apr;222:70-100. doi: 10.1111/j.1600-065X.2008.00603.x. Immunol Rev. 2008. PMID: 18363995 Free PMC article. Review.
-
High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC).J Clin Pathol. 2006 Mar;59(3):255-9. doi: 10.1136/jcp.2005.027615. J Clin Pathol. 2006. PMID: 16505275 Free PMC article.
-
ZD1839 ('Iressa') as an anticancer agent.Drugs. 2000;60 Suppl 1:33-40; discussion 41-2. doi: 10.2165/00003495-200060001-00004. Drugs. 2000. PMID: 11129170 Review.
-
Targeting EGFR in bladder cancer.World J Urol. 2007 Dec;25(6):573-9. doi: 10.1007/s00345-007-0202-7. Epub 2007 Aug 10. World J Urol. 2007. Retraction in: World J Urol. 2012 Oct;30(5):723. doi: 10.1007/s00345-012-0940-z. PMID: 17690890 Retracted.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous